Five things for pharma marketers to know: Wednesday, August 31, 2016

1. The FDA approved the first biosimilar version of Amgen's psoriasis and rheumatoid arthritis treatment Enbrel. The biosimilar, named Erelzi, is manufactured by Novartis' Sandoz business unit. (FDA)

2. Pharmacy benefit manager Express Scripts plans to launch a new program aimed at reducing patients' costs for diabetes care. The program is expected to launch in March of next year and will cap per-patient spending on diabetes and will also allow patients to receive 90-day supplies of their medicines from preferred pharmacies. (St. Louis Business Journal)

3. Bexsero, GlaxoSmithKline's meningitis B vaccine, is beating sales forecasts. GSK bought the vaccine from Novartis in March 2015. (Bloomberg)

4. Teva Pharmaceutical Industries is closing an R&D plant in Pomona, New York, and eliminating 236 jobs there. A spokesperson said 80 employees will be affected and that jobs will be shifted elsewhere. (Stat)

5. AstraZeneca will pay $5.52 million to settle a foreign bribery investigation into payments made by its sales and marketing teams to Chinese and Russian government employees. The Securities and Exchange Commission said that the British drugmaker did not maintain proper internal accounting controls for its interactions with Chinese and Russian government officials through 2010. (Reuters)